Latest:

Fat Pitch Financials

Special situation stocks and value investing

Stock Quote

Recent Quotes
My Watchlist
Indicators
Markets
Stocks
ETFs
Tools
Overview
News
Currencies
International
Treasuries

AbbVie (NY: ABBV )

134.91 +1.47 (+1.10%)
Streaming Delayed Price Updated: 11:05 AM EDT, Jun 2, 2023 Add to My Watchlist
Quote
Overview Detailed Quote Charting Historical Prices
News
All News News Headlines Press Releases
Research
Quarterly Reports Insider Filings Other Filings

Price and Volume

Detailed Quote
Volume 1,776,703
Open 133.71
Bid (Size) 134.90 (3)
Ask (Size) 134.93 (1)
Prev. Close 133.44
Today's Range 133.50 - 135.24
52wk Range 131.10 - 168.11
Shares Outstanding N/A
Dividend Yield 3.85%
Chart for (: )
Intraday 1 Week 1 Month 3 Month 1 Year 3 Year 5 Year

Top News

More News
7 Best Dividend Stocks to Buy Now in June 2023
These top dividend stocks are attractive at these levels and lower, and they add excellent diversity to a long-term investing portfolio. 
Via The Motley Fool
Mark Cuban Helping Lower Cost Of Bestselling Humira With Cost Plus Drug Company: 'The Game Just Changed'
One of the bestselling medical drugs of all time has come off patent. The result could mean lower costs for those who need the drug as a treatment option. Enter Mark Cuban and his Cost Plus Drug... 
Via Benzinga

Performance

YTD
-16.92%
-16.92%
1 Month
-11.02%
-11.02%
3 Month
-12.61%
-12.61%
6 Month
-16.53%
-16.53%
1 Year
-7.61%
-7.61%

More News

Read More
Why Is AbbVie Stock Trading Down Today?
Via Benzinga
Why AbbVie and Amgen Are Moving Lower Today
Via The Motley Fool
AbbVie Unusual Options Activity
Via Benzinga
2 Dividend Kings on Sale That Are Yielding More Than 4%
Via The Motley Fool
2 Top Dividend Kings to Buy for the Long Haul
Via The Motley Fool
AbbVie Unusual Options Activity
Via Benzinga
If You Invested $1000 In This Stock 10 Years Ago, You Would Have $3,200 Today
Via Benzinga
Wall Street's Most Accurate Analysts Say Buy These 3 Health Care Stocks With Over 3% Dividend Yields
Via Benzinga
Clinical Triumph: MEI Pharma's Voruciclib Demonstrates Encouraging Activity in AML Patients
Via Benzinga
Why Ironwood Pharmaceuticals Stock Bumped Higher Today
Via The Motley Fool
AbbVie Unusual Options Activity
Via Benzinga
VectivBio Stock Catapults 38% After Ironwood Agrees To Buy It For $1 Billion
Via Investor's Business Daily
3 Relatively Safe Stocks to Buy if a Recession Is on the Way
Via The Motley Fool
What Does AbbVie's Debt Look Like?
Via Benzinga
This Is What Whales Are Betting On AbbVie
Via Benzinga
P/E Ratio Insights for AbbVie
Via Benzinga
Peering Into AbbVie's Recent Short Interest
Via Benzinga
3 No-Brainer Dividend Stocks to Buy With $1,000 Right Now
Via The Motley Fool
FDA Approves AbbVie/Genmab's Cancer Drug As First Bispecific Antibody For Type Of Lymphoma In Adult Patients
Via Benzinga
FDA Approves First Oral Treatment For Crohn's Disease, Making Seventh Approval For AbbVie's Rinvoq
Via Benzinga
Apple Thwarts $2B In Fraud Transactions, UBS Takes $17B Hit From 'Hasty Credit Suisse Takeover,' Verizon Streamlines Unlimited Data Plans: Today's Top Stories
Via Benzinga
One More Quits US Pharma Lobby Group: AstraZeneca Follows Teva, AbbVie Footsteps
Via Benzinga
Pfizer CEO Fires Back On US Drug Pricing Reforms: 'Negotiation with a Gun to Your Head'
Via Benzinga
Data & News supplied by www.cloudquote.io
Stock quotes supplied by Barchart
Quotes delayed at least 20 minutes.
By accessing this page, you agree to the following
Privacy Policy and Terms and Conditions.